GT201000102A - Producto de dispersión sólida de drogas basadas en n-aril urea - Google Patents

Producto de dispersión sólida de drogas basadas en n-aril urea

Info

Publication number
GT201000102A
GT201000102A GT201000102A GT201000102A GT201000102A GT 201000102 A GT201000102 A GT 201000102A GT 201000102 A GT201000102 A GT 201000102A GT 201000102 A GT201000102 A GT 201000102A GT 201000102 A GT201000102 A GT 201000102A
Authority
GT
Guatemala
Prior art keywords
aril
solid dispersion
urea
dispersion product
based drugs
Prior art date
Application number
GT201000102A
Other languages
English (en)
Spanish (es)
Inventor
Rudolf Schroeder
Tanja Heitermann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201000102A publication Critical patent/GT201000102A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GT201000102A 2007-10-19 2010-04-16 Producto de dispersión sólida de drogas basadas en n-aril urea GT201000102A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99961807P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
GT201000102A true GT201000102A (es) 2012-03-12

Family

ID=40089463

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000102A GT201000102A (es) 2007-10-19 2010-04-16 Producto de dispersión sólida de drogas basadas en n-aril urea

Country Status (18)

Country Link
EP (1) EP2197425A2 (pt)
JP (1) JP2011500649A (pt)
KR (1) KR20100087170A (pt)
CN (1) CN101827584A (pt)
AU (1) AU2008313622A1 (pt)
BR (1) BRPI0818340A2 (pt)
CA (1) CA2699301A1 (pt)
CO (1) CO6270206A2 (pt)
CR (1) CR11442A (pt)
DO (1) DOP2010000117A (pt)
EC (1) ECSP10010183A (pt)
GT (1) GT201000102A (pt)
MX (1) MX2010004291A (pt)
PA (1) PA8800101A1 (pt)
RU (1) RU2010119929A (pt)
UA (1) UA100865C2 (pt)
WO (1) WO2009050291A2 (pt)
ZA (1) ZA201002095B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
RU2566716C2 (ru) 2010-06-09 2015-10-27 Эббви Бахамаз Лтд. Твердые дисперсии, содержащие ингибиторы киназ
JP6150813B2 (ja) 2011-11-11 2017-06-21 ノバルティス アーゲー 増殖性疾患の治療方法
CA2856406C (en) * 2011-11-23 2020-06-23 Novartis Ag Pharmaceutical formulations
WO2014003677A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising solid dispersion particles containing tadalafil
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2626579A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
WO2008055966A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
ECSP10010183A (es) 2010-06-29
BRPI0818340A2 (pt) 2015-04-22
RU2010119929A (ru) 2011-11-27
UA100865C2 (ru) 2013-02-11
AU2008313622A1 (en) 2009-04-23
MX2010004291A (es) 2010-08-02
WO2009050291A2 (en) 2009-04-23
CR11442A (es) 2010-09-06
DOP2010000117A (es) 2010-05-15
CN101827584A (zh) 2010-09-08
ZA201002095B (en) 2011-11-30
JP2011500649A (ja) 2011-01-06
CA2699301A1 (en) 2009-04-23
WO2009050291A3 (en) 2010-04-08
CO6270206A2 (es) 2011-04-20
EP2197425A2 (en) 2010-06-23
KR20100087170A (ko) 2010-08-03
PA8800101A1 (es) 2009-05-15

Similar Documents

Publication Publication Date Title
GT201000095A (es) Producto de dispersión sólida que contiene un compuesto a base de n-aril urea
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
EP2917180A4 (en) GPR40 RECEPTOR AGONIST, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREFORE AS AN ACTIVE SUBSTANCE
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2011001497A1 (es) Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico.
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
CL2013000675A1 (es) Compuestos derivados de pirazolamida sustituidas, con actividad sobre pge2/ep4; composicion farmaceutica que los comprende; y su uso para el tratamiento de la esclerosis multiple y la artritis reumtoide.
WO2014059444A3 (en) Chemical engines and methods for their use, especially in the injection of highly viscous fluids
CL2007002971A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
AR051969A1 (es) Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y el manejo de lesiones del sistema nervioso central
ECSP10010183A (es) Producto de dispersión sólida de drogas basadas en n-aril-urea
BR112015023434A8 (pt) compostos inibidores de histona deacetilase, seu uso e composição farmacêutica que os compreende
CL2009001215A1 (es) Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer.
CL2007003557A1 (es) Compuestos derivados de heterociclos de nitrogeno, inhibidores de la actividad sobre b-raf; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
AR072685A1 (es) Composicion topica para el tratamiento de queratosis actinica
CL2014003429A1 (es) Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
CL2007002970A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
BR112013020841B8 (pt) Processo para preparar produtos que compreendem ativos estabilizados e composições que compreendem os mesmos
CO2018001918A2 (es) Moléculas basadas en urea como plaguicidas, e intermediarios, composiciones y procesos, relacionados con ellas
GB201105050D0 (en) Pharmaceutical agent
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0910912A2 (pt) Composto, prodroga, ativador de glicocinase, agente farmacêutico, e, uso do composto
EP3725331A4 (en) MODIFIED CARBON NANOMATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITION